熱門資訊> 正文

MannKind的Furoscix自动注射装置正在接受FDA审查以扩大标签

2025-12-01 22:21

MannKind Corporation (MNKD) said that the U.S. FDA has accepted its supplemental new drug application for the Furoscix ReadyFlow Autoinjector.
This device is designed to help patients administer their medication more easily.
The FDA has set a target action date of July 26, 2026.
The sNDA is backed by encouraging results from studies that were shared in August 2024.

More on MannKind

MannKind Corporation (MNKD) Discusses Discontinuation of ICoN-1 Phase III Trial for Nebulized Clofazimine in NTM Lung Disease Transcript
MannKind Corporation 2025 Q3 - Results - Earnings Call Presentation
MannKind Corporation (MNKD) Q3 2025 Earnings Call Transcript
MannKind slides after halting late-stage trial of MNKD-101 for lung disease
MannKind outlines FUROSCIX market expansion and Afrezza pediatric launch strategy following record $82M Q3 revenue

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。